JMP Securities Raises Aura Biosciences (NASDAQ:AURA) Price Target to $23.00

Aura Biosciences (NASDAQ:AURA) had its target price raised by JMP Securities from $19.00 to $23.00 in a research report released on Friday, Benzinga reports. The brokerage currently has a market outperform rating on the stock.

A number of other analysts also recently commented on AURA. Lifesci Capital upgraded Aura Biosciences to a strong-buy rating in a research report on Monday, September 9th. HC Wainwright started coverage on shares of Aura Biosciences in a research report on Thursday, July 25th. They issued a buy rating and a $21.00 price objective on the stock.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $10.07 on Friday. Aura Biosciences has a one year low of $5.99 and a one year high of $12.35. The company has a market cap of $498.90 million, a P/E ratio of -5.41 and a beta of 0.35. The business has a fifty day moving average of $8.52 and a two-hundred day moving average of $7.87.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. Sell-side analysts predict that Aura Biosciences will post -1.7 EPS for the current year.

Institutional Trading of Aura Biosciences

A number of large investors have recently made changes to their positions in the stock. Trexquant Investment LP boosted its position in Aura Biosciences by 64.5% during the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock worth $154,000 after acquiring an additional 6,809 shares during the last quarter. Franklin Resources Inc. acquired a new stake in Aura Biosciences in the 4th quarter worth about $5,317,000. TBH Global Asset Management LLC grew its holdings in Aura Biosciences by 82.3% in the 4th quarter. TBH Global Asset Management LLC now owns 60,322 shares of the company’s stock valued at $534,000 after buying an additional 27,225 shares during the period. Decheng Capital LLC acquired a new position in shares of Aura Biosciences during the 4th quarter valued at about $4,568,000. Finally, Monashee Investment Management LLC acquired a new position in shares of Aura Biosciences during the 4th quarter valued at about $1,758,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.